1Ilson DH. Oesophageal cancer: new developments in systemic therapy[ J ]. Cancer Treat Rev ,2003,29 (6) :525 - 532.
2Anderson SE, Minsky BD, Bains M, et al . Combined modality therapy in esophagealcancer: the Memoria experience [ J ]. Semin Surg Oncol,2003,21 (4) :228 -232.
3Hara F, Aoe M, Doihara H, et al. Antitumor effect of gefitinib (Iressa) on esophageal squamous cell carcinoma cell lines in vitro and vivo[ J]. Cancer Lett,2005,226( 1 ) :37 -47.
4Ferry DR, Anderson M, Beddard K, et al. A phasell study of gefitinib monotherapy in advanced esophageal adenocardnoma: evidence of gene expression, cellular, and clinical response [ J]. Clin Cancer Res,2007,13 ( 19 ) :5869 - 5875.
5Janmaat ML, Gallegos - Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second - line treatment of advanced esophageal carlcer patients [J]. J Clin Oncol,2006,24(10) :1612 - 1619.
